ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="Nelson Vergel" data-source="post: 16066" data-attributes="member: 3"><p>Finally, a promising study.</p><p></p><p></p><p><strong>Risk for venous thrombotic events no higher in men with hypogonadism on testosterone therapy</strong></p><p></p><p>March 11, 2015</p><p></p><p> </p><p>SAN DIEGO — Men with hypogonadism do not appear to have any increased risk for venous thrombotic events with exogenous testosterone replacement therapy, according to research presented at The Endocrine Society annual meeting.</p><p></p><p></p><p>“After carefully designing and evaluating real-world evidence data, we failed to find a positive relationship between testosterone replacement therapy and idiopathic venous thrombotic events,” Hu Li, MBBS, PhD, of Eli Lilly and Company, Indianapolis, Indiana, told Endocrine Today.</p><p></p><p>“Although the study is observational in nature with its own limitation, it provides valuable information to physicians and patients in addition to spontaneously reported cases,” he said.</p><p></p><p>In a retrospective cohort and nested-case-control analyses, Li and colleagues investigated the relationships between testosterone replacement therapy (TRT) and venous thrombotic events (VTE) among adult men with hypogonadism aged at least 18 years.</p><p></p><p>The investigators searched Truven Databases to obtain data on men with a hypogonadal condition, defined as being treated with an approved TRT product or untreated but having a hypogonadal diagnosis per International Classification of Diseases criteria. Patients had been enrolled in a health care plan for at least 12 months and had no VTE diagnosis at baseline.</p><p></p><p>After propensity score matching in a 1:1 ratio to ensure comparability, 102,650 patients treated with TRT and 102,650 untreated patients with idiopathic VTE were included.</p><p></p><p>Treated and untreated patients were then matched in a 1:4 ratio based on age and calendar year.</p><p></p><p>Index date among treated men (n = 2,785) was defined as the first TRT prescription and among untreated men (n = 11,119) was assigned at random according to the distribution for those treated. Incident VTE, and primarily idiopathic VTE, was the main outcome sought. The researchers assessed exposure as any TRT use and different administration methods.</p><p></p><p>Cox regression and conditional logistic regression models were used in the cohort and nested analyses to assess, respectively, HRs and ORs for relationships between TRT and VTE. Sensitivity analyses were performed with varied TRT exposure and VTE parameters. </p><p></p><p>In the retrospective cohort analysis, the HR for patients treated with any TRT was 1.08 (95% CI, 0.91-1.27), with topical/gel TRT was 1.07 (95% CI, 0.88-1.29) and with injectable TRT was 1.32 (95% CI, 0.89-1.96). The results were not significant when men were stratified by age.</p><p></p><p>Nested analyses of treated and untreated groups revealed similar, but not significant findings. The likelihood of having VTE with current TRT use was slightly higher than past TRT use (OR = 1.02; 95% CI, 0.92-1.13 vs. OR = 0.92; 95% CI, 0.82-1.03). When patients were stratified by age and TRT administration, results were similar but nonsignificant.</p><p></p><p>“Future studies are warranted to confirm the study findings,” Li said. “Regardless of this study finding, Lilly has updated the Axiron U.S. product label and the Medication Guide to reflect the additional language requested by FDA related to thromboembolic risk.” &#8211; by Allegra Tiver</p><p></p><p>Reference:</p><p></p><p>Li H. Abstract OR34-2. Presented at: The Endocrine Society Annual Meeting; March 5-8, 2015, San Diego. </p><p></p><p>Disclosure: Li reports being an employee at Eli Lilly & Company.</p></blockquote><p></p>
[QUOTE="Nelson Vergel, post: 16066, member: 3"] Finally, a promising study. [B]Risk for venous thrombotic events no higher in men with hypogonadism on testosterone therapy[/B] March 11, 2015 SAN DIEGO — Men with hypogonadism do not appear to have any increased risk for venous thrombotic events with exogenous testosterone replacement therapy, according to research presented at The Endocrine Society annual meeting. “After carefully designing and evaluating real-world evidence data, we failed to find a positive relationship between testosterone replacement therapy and idiopathic venous thrombotic events,” Hu Li, MBBS, PhD, of Eli Lilly and Company, Indianapolis, Indiana, told Endocrine Today. “Although the study is observational in nature with its own limitation, it provides valuable information to physicians and patients in addition to spontaneously reported cases,” he said. In a retrospective cohort and nested-case-control analyses, Li and colleagues investigated the relationships between testosterone replacement therapy (TRT) and venous thrombotic events (VTE) among adult men with hypogonadism aged at least 18 years. The investigators searched Truven Databases to obtain data on men with a hypogonadal condition, defined as being treated with an approved TRT product or untreated but having a hypogonadal diagnosis per International Classification of Diseases criteria. Patients had been enrolled in a health care plan for at least 12 months and had no VTE diagnosis at baseline. After propensity score matching in a 1:1 ratio to ensure comparability, 102,650 patients treated with TRT and 102,650 untreated patients with idiopathic VTE were included. Treated and untreated patients were then matched in a 1:4 ratio based on age and calendar year. Index date among treated men (n = 2,785) was defined as the first TRT prescription and among untreated men (n = 11,119) was assigned at random according to the distribution for those treated. Incident VTE, and primarily idiopathic VTE, was the main outcome sought. The researchers assessed exposure as any TRT use and different administration methods. Cox regression and conditional logistic regression models were used in the cohort and nested analyses to assess, respectively, HRs and ORs for relationships between TRT and VTE. Sensitivity analyses were performed with varied TRT exposure and VTE parameters. In the retrospective cohort analysis, the HR for patients treated with any TRT was 1.08 (95% CI, 0.91-1.27), with topical/gel TRT was 1.07 (95% CI, 0.88-1.29) and with injectable TRT was 1.32 (95% CI, 0.89-1.96). The results were not significant when men were stratified by age. Nested analyses of treated and untreated groups revealed similar, but not significant findings. The likelihood of having VTE with current TRT use was slightly higher than past TRT use (OR = 1.02; 95% CI, 0.92-1.13 vs. OR = 0.92; 95% CI, 0.82-1.03). When patients were stratified by age and TRT administration, results were similar but nonsignificant. “Future studies are warranted to confirm the study findings,” Li said. “Regardless of this study finding, Lilly has updated the Axiron U.S. product label and the Medication Guide to reflect the additional language requested by FDA related to thromboembolic risk.” – by Allegra Tiver Reference: Li H. Abstract OR34-2. Presented at: The Endocrine Society Annual Meeting; March 5-8, 2015, San Diego. Disclosure: Li reports being an employee at Eli Lilly & Company. [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone Side Effect Management
Can Testosterone Induce Blood Clots and Thrombosis? Interview with Dr Charles Glueck
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top